BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Graham DY. Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship. Antibiotics (Basel) 2020;9:E671. [PMID: 33023041 DOI: 10.3390/antibiotics9100671] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O'Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022:gutjnl-2022-327745. [PMID: 35944925 DOI: 10.1136/gutjnl-2022-327745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhong Z, Zhan B, Xu B, Gao H. Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization. Helicobacter 2022;:e12916. [PMID: 35939537 DOI: 10.1111/hel.12916] [Reference Citation Analysis]
3 Chakrapani G, Zare M, Ramakrishna S. Current Trends and Definitions in High-performance Antimicrobial Strategies. Current Opinion in Biomedical Engineering 2022. [DOI: 10.1016/j.cobme.2022.100407] [Reference Citation Analysis]
4 Ho JJC, Navarro M, Sawyer K, Elfanagely Y, Moss SF. Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2022;117:1221-30. [PMID: 35509128 DOI: 10.14309/ajg.0000000000001828] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Graham DY, Moss SF. Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, Why. Am J Gastroenterol 2022;117:524-8. [PMID: 35081545 DOI: 10.14309/ajg.0000000000001659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Krzyżek P, Migdał P, Grande R, Gościniak G. Biofilm Formation of Helicobacter pylori in Both Static and Microfluidic Conditions Is Associated With Resistance to Clarithromycin. Front Cell Infect Microbiol 2022;12:868905. [DOI: 10.3389/fcimb.2022.868905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Graham DY, Hernaez R, Rokkas T. Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy. Gut 2022;71:643-50. [PMID: 34750206 DOI: 10.1136/gutjnl-2021-326170] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Shiotani A, Roy P, Lu H, Graham DY. Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Therap Adv Gastroenterol 2021;14:17562848211064080. [PMID: 34987609 DOI: 10.1177/17562848211064080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Rokkas T, Georgopoulos S, Michopoulos S, Ntouli V, Liatsos C, Puig I, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Assessment of first-line eradication treatment in Greece: data from the European Registry on Helicobacter pylori management (Hp-EuReg). Ann Gastroenterol 2022;35:42-7. [PMID: 34987287 DOI: 10.20524/aog.2021.0670] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Krzyżek P, Junka A, Słupski W, Dołowacka-Jóźwiak A, Płachno BJ, Sobiecka A, Matkowski A, Chodaczek G, Płusa T, Gościniak G, Zielińska S. Antibiofilm and Antimicrobial-Enhancing Activity of Chelidonium majus and Corydalis cheilanthifolia Extracts against Multidrug-Resistant Helicobacter pylori. Pathogens 2021;10:1033. [PMID: 34451497 DOI: 10.3390/pathogens10081033] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
11 Goodman C, Lyon KN, Scotto A, Smith C, Sebrell TA, Gentry AB, Bala G, Stoner GD, Bimczok D. A High-Throughput Metabolic Microarray Assay Reveals Antibacterial Effects of Black and Red Raspberries and Blackberries against Helicobacter pylori Infection. Antibiotics (Basel) 2021;10:845. [PMID: 34356766 DOI: 10.3390/antibiotics10070845] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Gunaratne AW, Hamblin H, Clancy A, Magat AJMC, Dawson MVM, Tu J, Borody TJ. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study. Helicobacter 2021;:e12830. [PMID: 34247436 DOI: 10.1111/hel.12830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Perkovic N, Mestrovic A, Bozic J, Ivelja MP, Vukovic J, Kardum G, Sundov Z, Tonkic M, Puljiz Z, Vukojevic K, Tonkic A. Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection. J Pers Med 2021;11:534. [PMID: 34207870 DOI: 10.3390/jpm11060534] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology 2021;161:495-507.e4. [PMID: 33839101 DOI: 10.1053/j.gastro.2021.04.012] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
15 Hulten KG, Lamberth LB, Kalfus IN, Graham DY. National and Regional US Antibiotic Resistance to Helicobacter pylori: Lessons From a Clinical Trial. Gastroenterology 2021;161:342-344.e1. [PMID: 33798524 DOI: 10.1053/j.gastro.2021.03.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
16 Graham DY, Liou JM. Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00336-0. [PMID: 33775895 DOI: 10.1016/j.cgh.2021.03.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
17 Kang SJ, Jung H, Lee YC, Yang H, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Eradication Rates of Clarithromycin Triple Therapy in Korea: A Systematic Review and Meta-analysis. Korean J Helicobacter Up Gastrointest Res 2021;21:35-47. [DOI: 10.7704/kjhugr.2020.0056] [Reference Citation Analysis]
18 Graham DY, Megraud F. Classification system for Helicobacter pylori therapies: Compared and contrasted to traditional infectious disease therapy. Helicobacter 2021;26:e12773. [PMID: 33207391 DOI: 10.1111/hel.12773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]